PanAridus to join Cooper Tire and other Consortium Partners on $6.9 Million USDA Grant to Develop Guayule Plant-Based Polymer for Tire ApplicationsContinue reading
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High CholesterolContinue reading
The Biodesign Mass Spec facility is open to external users.
Ventana announces HER2 companion diagnostic to identify breast cancer patients for Roche’s latest targeted medicines, Perjeta and Kadcyla. VENTANA HER2 (4B5) IHC assay label expansion coincides with therapy availability in many non-U.S. countries globally
Rapid DNA processor helps contribute to Arizona’s economic developmentContinue reading
MINNEAPOLIS – December 9, 2013 – Continuing its leadership in advanced pacing technology and device miniaturization, Medtronic, Inc. (NYSE: MDT), today announced the first-in-human implant of the world’s smallest pacemaker: the Micra(TM) Transcatheter Pacing System (TPS). The device was implanted in a patient in Linz, Austria as part of the Medtronic global pivotal clinical trial. The Micra TPS is an investigational device worldwide.Continue reading
NIH grant to identify biomarker for secondary injuries associated with ruptured brain aneurysms and subarachnoid hemorrhageContinue reading
Launching a research study often takes years of work, and most of the effort occurs behind the scenes. The exciting news is that several of these studies have just launched or are close to being ready to start recruiting participants through the Alzheimer’s Prevention Registry. And more studies will launch in the coming years. Here is a snapshot of a few of the studies that will be taking place in the United States and other countries around the world:
- A trial in 1000 adults ages 65-85 who have evidence of amyloid plaque build up in their brain based on a screening PET scan, and who are at risk for Alzheimer’s disease but are still cognitively healthy to determine whether an experimental medication may delay cognitive decline
- A trial in nearly 6,000 adults ages 65-83 to learn about the genetic risk for developing mild cognitive impairment due to Alzheimer’s disease and whether an experimental medication might delay the symptoms
- Two trials in a rare, hereditary form of early-onset Alzheimer’s with experimental medications to determine if treatment delays cognitive impairment
- And many more.
Imagine having tens of thousands of volunteers awaiting an e-mail from the Registry announcing that a study is ready to begin enrollment in their communities. Researchers could quickly screen and fill their enrollment sites in a matter of weeks or months, not years. Saving this precious time means we get to answers faster.
This is why the Alzheimer’s Prevention Registry will play a vital role in these and other prevention trials.
Take action: While researchers work to get these and other studies ready, you can help by continuing to encourage your friends and family to sign up for the Registry.